NewslettersMuscle Cell NewsDyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular DystrophyBy Jamie Kang - October 31, 20220351Dyne Therapeutics, Inc. announced that the FDA has granted Fast Track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 51 skipping.[Dyne Therapeutics, Inc.]Press Release